Protagonist Therapeutics (PTGX) Liabilities and Shareholders Equity (2015 - 2026)

Protagonist Therapeutics has reported Liabilities and Shareholders Equity for 12 years, with the latest figure at $697.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 6.02% year-over-year to $697.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 billion (up 2.96% YoY) and the FY2025 annual result came in at $668.2 million, down 10.28% from the prior year.
• Liabilities and Shareholders Equity advanced to $697.5 million in Q1 2026 per PTGX's latest filing, from $668.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $744.7 million in Q4 2024 and troughed at $239.9 million in Q1 2023.
• A 5-year average of $503.4 million and a median of $603.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity tumbled 31.13% in 2023, then jumped 162.35% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $247.9 million in 2022, then soared by 44.38% to $358.0 million in 2023, then jumped by 108.05% to $744.7 million in 2024, then fell by 10.28% to $668.2 million in 2025, then grew by 4.38% to $697.5 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $697.5 million, $668.2 million, and $701.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.